Moleac Announces Breakthrough Results on Neuroprotective and
Neurogenerative Properties of NeuroAiD
2010-02-11 14:00
SINGAPORE, Feb. 11 /PRNewswire-Asia/ -- The January issue
of "Neuropharmacology", publishes the article entitled
"Neuroprotective and neuroproliferative activities of NeuroAiD",
reporting pharmacological data establishing NeuroAiD (MLC 601)
protective effects on neuronal and brain injuries as well as its
effectiveness in neurological functions recovery.
The French research team was lead by Prof.
Michel Lazdunski, world-renowned specialist of pharmacology.
The data demonstrates NeuroAiD effects on
decreasing cognitive deficits, preventing death of threatened
neuronal tissues and improving functional outcomes by repairing and
restoring neuronal circuits. This is fully consistent with clinical
observations of NeuroAiD efficacy as a post stroke treatment.
NeuroAiD treatment increases survival rate,
reduce infarct volume, prevent neuronal death and drastically
decreased functional deficits in rodents' stroke models. The data
also showed NeuroAiD's effectiveness in reducing stroke severity
when administrated preventively.
The results show that NeuroAiD triggers the
synthesis of Brain Derived Neurotrophic Factor (BDNF), which is
known to promote neuroplasticity. Indeed NeuroAiD induces
neurogenesis in rodent and human cells, and stimulates the
development of new neuronal circuits of information.
Previous trials and clinical reports
conducted in Asia have already demonstrated high levels of NeuroAiD
safety and efficacy in improving stroke rehabilitation, even when
taken several months after stroke onset. NeuroAiD Stroke Treatment
is already available in many countries in Asia and in the Middle
East for stroke survivors. New clinical assessments will be
conducted in France and Europe shortly on stroke recovery.
David Picard, CEO of Moleac, said "We are
extremely enthusiastic and proud to see these data published. It is
a strong validation of our research of active ingredients in
NeuroAiD as well as of our efforts towards continuous optimization
of its formula. These results pave the way for new indications of
NeuroAiD beyond stroke recovery such as prevention, cognitive
impairments and dementia. It is good news for patients who are in
need of treatment in this under-served therapeutic area."
About Moleac
Moleac is a Singapore-based biopharmaceutical
company that dedicates itself in finding and developing new
medicines for the unmet needs of patients worldwide. http://www.moleac.net
About NeuroAiD
NeuroAiD is a stroke treatment to help stroke
patients achieve faster and better recovery. NeuroAiD is derived
from natural components, carefully selected for their efficacy and
absence of side effects. It currently reaches out to patients in
over 25 countries. http://www.neuroaid.com
Contact details:
Kasia Kaminska
Tel: +65-64789432
[email protected]
SOURCE Moleac